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Strengths and limitations of this study
 ► This is the first prospective study to compare clinical 
impression-based strategies, prediction-rules and 
hs-troponin-based strategies for ruling-out non-
ST elevation myocardial infarction in patients with 
symptoms suggestive of acute coronary syndrome 
in emergency department (ED).
 ► We will also evaluate the inter-rater reliability of 
the clinical impression-based risk estimation and 
discuss the usefulness of the strategies consider-
ing both the diagnostic accuracy and the inter-rater 
reliability.
 ► We will use three high-sensitive-troponin and one 
sensitive-troponin which are currently widely avail-
able in order to increase the applicability of the re-
sults of our study.
 ► A limitation of the study is that troponin will rare-
ly be taken later than 3 hours after presentation to 
ED and we follow-up patients mainly by telephone 
interview, and therefore, we may miss some sub-
sequent myocardial infarctions (MIs), although it is 
very unlikely that patients will have a MI and not 
reattend hospital.
 ► Because the study population is only from Japan, 
the generalisability of the results might be limited, 
although the prevalence of MI varies largely among 
previous studies and that of our study will be some-
where among them.
AbStrACt
Introduction Recent advances in troponin sensitivity 
enabled early and accurate judgement of ruling-out 
myocardial infarction, especially non-ST elevation 
myocardial infarction (NSTEMI) in emergency 
departments (EDs) with development of various 
prediction-rules and high-sensitive-troponin-
based strategies (hs-troponin). Reliance on clinical 
impression, however, is still common, and it remains 
unknown which of these strategies is superior. 
Therefore, our objective in this prospective cohort 
study is to comprehensively validate the diagnostic 
accuracy of clinical impression-based strategies, 
prediction-rules and hs-troponin-based strategies for 
ruling-out NSTEMIs.
Methods and analysis In total, 1500 consecutive 
adult patients with symptoms suggestive of acute 
coronary syndrome will be prospectively recruited 
from five EDs in two tertiary-level, two secondary-
level community hospitals and one university 
hospital in Japan. The study has begun in July 
2018, and recruitment period will be about 1 year. A 
board-certified emergency physician will complete 
standardised case report forms, and independently 
perform a clinical impression-based risk estimation of 
NSTEMI. Index strategies to be compared will include 
the clinical impression-based strategy; prediction rules 
and hs-troponin-based strategies for the following 
types of troponin (Roche Elecsys hs-troponin T; Abbott 
ARCHITECT hs-troponin I; Siemens ADVIA Centaur hs-
troponin I; Siemens ADVIA Centaur sensitive-troponin I). 
The reference standard will be the composite of type 1 
MI and cardiac death within 30 days after admission to 
the ED. Outcome measures will be negative predictive 
value, sensitivity and effectiveness, defined as the 
proportion of patients categorised as low risk for 
NSTEMI. We will also evaluate inter-rater reliability of 
the clinical impression-based risk estimation.
Ethics and dissemination The study is approved 
by the Ethics Committees of the Kyoto University 
Graduate School and Faculty of Medicine and of the 
five hospitals where we will recruit patients. We will 
disseminate the study results through conference 
presentations and peer-reviewed journals.
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IntroduCtIon
background
Because ruling-out non-ST elevation myocardial infarc-
tions (NSTEMIs) is often challenging, the American 
College of Cardiology (ACC)/American Heart Associa-
tion (AHA) and European Society of Cardiology (ESC) 
2007 guidelines mandate the serial troponin tests over 
a period of 6–12 hours after symptom onset or admis-
sion to the emergency department (ED).1 2 This long 
period of observation is the principal reason for admit-
ting patients with symptoms that might be related to 
an myocardial infarction (MI) and is, in fact, the most 
frequent reason for admission in ED in both the UK 
and the USA.3 4 However, between 75% and 95% of 
patients presenting to the EDs with symptoms sugges-
tive of MI did not have MI.5 6 Therefore, earlier and 
safer strategies to rule-out an MI in EDs, which would 
allow patients to be discharged directly from the ED, 
have been in a great demand. It is generally accepted 
that the risk of MI and death within 30 days should be 
<1–2% to patients directly discharged from the ED.7 8
Recently, several high-sensitive-troponins (hs-tro-
ponin) have decreased the recommended time for 
troponin monitoring for MI diagnosis to 3–6 hours 
(2014 ACC/AHA guidelines9), and further to 0–3 hours 
(2015 ESC guidelines10). Furthermore, a large indi-
vidual patient-level data meta-analysis reported that 
when the initial troponin value was much lower than the 
99th percentile, the negative predictive value (NPV) was 
consistently >99% across the included cohorts.6 There-
fore, the time frame of serial troponin monitoring 
could be greatly shortened, or even made unnecessary, 
for certain populations. The population in East Asia 
may be appropriate for very early ‘ruling-out’ strategies 
of MI since the incidence of MI in East Asia, especially 
in Japan, is much lower than in Western countries.11
Although troponin is crucial for the accurate diag-
nosis of MI, the clinical history, physical findings and 
ECG are also essential. Several clinical decision-making 
models have been developed for MI, including the 
clinical impression-based strategy, prediction rules and 
the hs-troponin-based strategy. The clinical impres-
sion-based strategy is a traditional approach where 
clinical gestalt is used to estimate risk based on the 
history and physical findings, and review of the ECG 
and troponin. Although few reports are available, this 
approach remains common in practice, especially in 
Japan. However, the inter-rater reliability of the risk 
estimation for MI based on clinical impression has not 
been comprehensively evaluated, and previous studies 
suggested that risk estimation for MI varies greatly, 
depending on the physician’s experience and back-
ground.12 13
Prediction rules have been developed that consider 
clinical findings and troponin monitoring in a struc-
tured way to determine the risk of an MI. Several 
prediction rules to estimate the risk of an MI have 
been defined, including the TIMI,14 HEART,15 
EDACS16 and T-MACS17 rules. Most of the newer 
prediction rules that have incorporated hs-troponin 
have achieved an NPV of >99% and have been vali-
dated.18–21 Prediction rules, however, are not widely 
used, despite their excellent NPVs, partly because 
they have not been compared against clinical impres-
sion-based strategies.22
There are several hs-troponin-based strategies that use 
only hs-troponin, such as the 0 and 1 hour algorithm,23 
the 0 and 2 hour algorithm24 and the High-STEACS 
pathway.25 These strategies are simple, and they rely on 
a measurement of hs-troponin only, with demonstrated 
NPVs of >99%. Hs-troponin assays have excellent preci-
sion at very low concentrations with very few analytical 
false positives.26 On the other hand, the clinical history, 
physical findings and ECG readings are sometimes not 
reliable, and different physicians often have different 
interpretations.13 27 Although they are essential compo-
nents of a comprehensive clinical assessment, the first 
risk stratification might be better to be based on some-
thing that is highly reliable, with subsequent risk strati-
fication performed using clinical judgement, especially 
in ED where physicians with differing backgrounds 
and experience work. However, the cutoffs of troponin 
levels in these hs-troponin strategies tend to be much 
lower than the 99th percentile and patient age, which 
has previously been associated with an increase in 
troponin level,28 29 may affect the proportion of patients 
to be ruled-out. As such, hs-troponin-based strategies 
may be less efficient in highly aged populations, such 
as in Japan.
rationale for the study
First, although many strategies to rule-out MI have been 
proposed, a comprehensive prospective validation of the 
clinical impression-based strategies, prediction-rules and 
hs-troponin-based strategies to rule-out MI has not been 
performed.
Second, although the use of serial troponin and the 
cutoffs below the 99th percentile of troponin are recom-
mended in Western countries, it has not yet been proven 
well in East Asia, where the incidence of MI is low and reli-
ance on the clinical impression-based strategy is common.11 
Because serial troponin is not only time consuming, but 
requires additional resources and medical expenses, there 
is a need, particularly in East Asia, to evaluate the NPV 
of clinical impression-based strategies, combined with 
troponin levels obtained at different time points, using the 
99th percentile cut-off value.
Third, although many kinds of troponins are now avail-
able, the diagnostic accuracy and cut-off are each troponin 
specific. Our proposed study will include the four types of 
troponin that are currently widely available: Roche hs-tro-
ponin T; Abbott hs-troponin I; Siemens hs-troponin I; 
Siemens sensitive-troponin I in order to increase the appli-
cability of our results to as many facilities as possible.
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Study objectives
Primary research objective
Our primary objective is to compare the NPV, sensitivity and 
effectiveness (defined as the proportion of patients cate-
gorised into low risk to all patients to whom a strategy was 
applied) of the three clinical impression-based strategies 
with three time frames of troponin monitoring: on arrival 
(0 hour) only; 0 and 1 hour after; and 0 and 2 hour after, 
using the composite outcome of cardiac death or the occur-
rence of a type 1 MI within 30 days of the ED consultation.
Secondary research objectives
Our secondary research objectives are:
1. To validate and compare the NPV, sensitivity and effec-
tiveness between clinical impression-based strategies, 
prediction rules and hs-troponin-based strategies.
2. To evaluate the inter-rater reliability of the clinical 
impression-based strategy, in estimating the risk esti-
mation of an MI, when performed by board-certified 
emergency physicians and senior residents of emer-
gency medicine, general internists, cardiologists, ju-
nior residents and nurses.
MEthodS And AnAlySIS
Setting
We will recruit patients from five EDs in two tertiary-level 
community hospitals (Fukui Prefectural Hospital, Nagoya 
East Medical Center), two secondary-level community 
hospitals (Fukui-ken Saiseikai Hospital, Japanese Red 
Cross Fukui Hospital) and one university hospital (Fukui 
University Hospital) in Japan. Because patient recruit-
ment is slow, we are adding a number of hospitals. We 
have purposively selected hospitals which cover the 
majority of emergency cases in the rural as well as urban 
to suburban areas.
Inclusion criteria
1. Age ≥25 years.
2. Have any one of the following symptoms suspected to 
be MI.
a. Chest pain.
b. Non-chest pain, including radiating pain, syncope, 
dyspnea, nausea/vomiting and fatigue, and other 
symptoms which emergency physicians judge to 
need to rule out an MI.
3. Presentation to the ED within 6 hours from symptom 
onset. We will set the threshold at 6 hours to focus on 
early presenters, the most difficult population to rule-
out NSTEMI very early.30
4. No apparent ST elevation on arrival.
5. The use of both ECG and the troponin test, as deemed 
to be required by the ED physician.
Exclusion criteria
1. Cardiopulmonary arrest on arrival.
2. Non-cardiac terminal illness (expected survival 
<6 months).
3. Need for resuscitation (physiological shock, continu-
ous oxygen administration).
4. Indication of emergency catheterisation on arrival.
5. Inability of the patient to provide consent.
6. Previous inclusion in the study.
7. Unable to contact for follow-up after 30 days.
8. Unknown time of onset of symptoms.
9. Apparent need to admit for a diagnosis other than 
acute coronary syndrome on arrival.
10. Patients on maintenance dialysis.
11. Judged as ineligible by an emergency physician.
Participants recruitment
When an MI is suspected, an ECG will be obtained first, as 
per usual practice. If there is no significant ST elevation, 
a board-certified emergency physician will assess the eligi-
bility of the patient for enrolment into the study. Because 
board-certified emergency physicians are not regularly 
available at night or on weekends in three of the partic-
ipating hospitals (Fukui-ken Saiseikai Hospital; Japanese 
Red Cross Fukui Hospital; and Nagoya East Medical 
Center), patients will only be recruited when board-cer-
tified emergency physicians are working in these centres. 
In the other two facilities (Fukui Prefectural Hospital and 
Fukui University Hospital), board-certified emergency 
physicians are available around the clock and, therefore, 
patients will be recruited as they present to the EDs. We 
will review the patient recruitment status regularly by 
checking clinical records of all patients who visit ED in 
all hospitals to ensure representativeness and minimise 
spectrum bias.
Informed consent
We will obtain written informed consent from all 
patients. Because MI is more common in the elderly, it 
may be sometimes difficult to obtain informed consent 
from some patients due to dementia. Because excluding 
these patients will impair the validity of the study, we will 
seek to obtain consent from patient’s authorised proxy 
in such cases. We will conduct this study in accordance 
with the Declaration of Helsinki and its amendments. 
This study is registered in the UMIN-CTR registry 
(UMIN 000029992).
Clinical assessments
The following assessments will be performed at each site 
using standardised case report forms (CRF): history; phys-
ical examination; clinical impression-based risk estimation; 
ECG; standard blood tests; ultrasonography; and troponin 
levels (using both in-house and research troponin types). 
Clinical impression-based risk estimation for a NSTEMI will 
be classified as low, intermediate or high for analysis. The 
certainty of each item of the clinical history and ECG will 
be measured using a 4-point Likert scale. The inter-rater 
reliability will be evaluated between a board-certified emer-
gency physician and one of the following medical staff: a 
board-certified emergency physician; an emergency medi-
cine resident; a junior resident; a general practitioner; 
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Table 1 The 99th percentile and LoD values for four types 
of troponin
Troponin
99th percentile
(ng/L)
LoD
(ng/L)
Roche Elecsys hs-troponin T (general) 14.0 3.0
Roche Elecsys hs-troponin T (male) 15.5
Roche Elecsys hs-troponin T (female) 9.0
Abbott ARCHITECT hs-troponin I 
(general)
26.2 1.9
Abbott ARCHITECT hs-troponin I (male) 34.2
Abbott ARCHITECT hs-troponin I 
(female)
15.6
Siemens ADVIA Centaur hs-troponin I 
(general)
46.5 2.2
Siemens ADVIA Centaur hs-troponin I 
(male)
58.1
Siemens ADVIA Centaur hs-troponin I 
(female)
39.6
Siemens ADVIA Centaur sensitive-
troponin I
40.0 6.0
LoD, limit of detection.
a cardiologist; or a nurse for 300 consecutive patients 
enrolled into the study. The following variables will be 
included for inter-rater reliability: clinical impression-based 
risk estimation; each item of the clinical history; ECG; ultra-
sonography. Assessors will not be provided with results of 
the troponin levels, ultrasonography examination or the 
previous assessment performed by another emergency 
physician or cardiologist before completion of the CRF. 
Because it will occasionally be difficult to mask this infor-
mation, we will report the masking status. Management of 
patients will be left to the discretion of treating emergency 
physicians and cardiologists, based on the results of in-house 
troponin measurements in each hospital. The indication of 
early invasive strategy will follow current guidelines.9 10 31 
We will check all CRF immediately after we receive them 
from hospitals. If there are some missing values, we will ask 
coresearchers and make efforts to retrieve them as much as 
possible.
troponin
We will evaluate the following four types of troponin, 
three high-sensitive and one sensitive. The 99th percen-
tile and the limit of detection values for the four types 
of troponin are summarised in table 1. We will use 
sex-specific 99th percentile values for three types of 
hs-troponin in sensitivity analyses. We will collect blood 
samples in serum tubes for troponin levels on arrival 
(0 hour); and at 1, 2 and 3 hours after the first blood 
draw. After centrifugation, serum samples will be stored 
at less than −20°C until measured in each manufactur-
er’s laboratory in a blinded fashion.
Index tests
We will evaluate the three types of decision-making 
models to rule-out MI: the clinical impression-based 
strategies, prediction rules and hs-troponin-based strat-
egies. An author (MT) searched PubMed (December 
2017) for prediction rules and hs-based strategies to 
rule-out MI in ED. We also consulted reviews on this 
topic to identify suitable decision-making models. 
Among identified prediction-rules and hs-tropo-
nin-based strategies, we selected those which were vali-
dated and showed an NPV of >99%, using any types 
of troponin. We will include strategies with troponin 
taken up to 2 hours apart from the first one. Because 
it generally takes about 1 hour to take the first blood 
sample, we will include strategies with troponin taken 
up to 3 hours from presentation. All the intervals of 
troponin sampling we showed below are the time from 
the first blood draw. Each troponin will be adapted for 
each strategy, as needed. We will define the troponin 
cut-off at the 99th percentile value, except for hs-tro-
ponin-based strategies, and the T-MACS. The troponin 
cutoffs for hs-troponin-based strategies are specific for 
each type of troponin, as detailed below. Troponin 
values will be incorporated as a continuous variable 
in the T-MACS. We will adopt cutoffs for each strategy 
in accordance with the original publication for each 
strategy. The details of each prediction rule are shown 
in the online supplementary appendix. All the index 
tests will be applied to a patient using prospectively 
collected clinical information after we complete patient 
recruitment.
The clinical impression-based strategies
1. The 0 hour model.
a. Clinical impression-based risk estimation for history 
and physical findings is not high risk.
b. No new ischaemic findings on ECG.
c. Troponin taken on arrival is below the 99th percen-
tile.
2. The 0 and 1 hour model.
a. Clinical impression-based risk estimation for history 
and physical findings is not high risk.
b. No new ischaemic findings on ECG.
c. Troponin taken on arrival and at 1 hour apart are 
both below the 99th percentile.
3. The 0 and 2 hour model.
a. Clinical impression-based risk estimation for history 
and physical findings is not high risk.
b. No new ischaemic findings on ECG.
c. Troponin taken on arrival and at 2 hour apart are 
both below the 99th percentile.
We will evaluate the clinical impression-based risk 
estimation for history and physical findings based on 
the AHA/ACC guideline32 and a systematic review.33 
We define the new ischaemic findings on ECG as an ST 
depression and negative T wave not known to be old. 
An ST depression is defined by a depression of 0.05 mV 
or more at J point in two or more contiguous leads. A 
negative T wave is defined by T wave inversions of 0.1 mV 
or more in two or more contiguous leads. If all three 
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components of each model are satisfied, we regard a 
patient as being at low risk for an MI.
Prediction rules
1. TIMI+2 hour troponin.34
a. Components: age, coronary risk factors, use of as-
pirin, significant coronary stenosis, severe angina, 
ECG and troponin (at 0 and 2 hours).
b. Cut-off: we will define the score of 0 as a low risk 
for MI.
2. HEART.15
a. Components: history, ECG, age, risk factors and tro-
ponin.
b. Cut-off: we will define the score of 0–3 and negative 
troponin as a low risk for MI.
3. EDACS.16
a. Components: age, sex, coronary artery disease or 
risk factors, symptoms, ECG and troponin (at 0 and 
2 hours).
b. Cut-off: we will define low risk when all three con-
ditions are satisfied, namely: a score < 16; no new 
ischaemia on ECG; and negative troponin at 0 and 
2 hours.
4. T-MACS.17
a. Components: (E) ECG ischaemia, (A) worsening or 
crescendo angina, (R) right arm or shoulder pain, 
(V) vomiting, (S) sweating observed, (H) hypoten-
sion (systolic blood pressure <100 mm Hg), (T) 
high-sensitivity troponin T concentration on arrival 
(ng/L).
b. Probability =1 / (1 + e−(1.713E + 0.847A + 0.607R + 1.417V + 2.058S 
+ 1.208H + 0.089T – 4.766)).
c. Cutoff: we will define low risk if the probability is 
<0.02.
5. TRUST.35
a. Components: typical new-onset chest pain at rest, 
pain the same as previous MI, pain not relieved by 
glyceryl trinitrate within 15 min, pain lasting >60 
min, pain occurring with increasing frequency, hy-
potension, acute shortness of breath, pain within 
6 weeks of an MI or revascularisation, ECG, hs-tro-
ponin (at 0 hour).
b. Cutoff: we will define low risk when all three condi-
tions are satisfied: the score of 0 or 1, non-ischaemic 
ECG and negative troponin.
6. GRACE.10
a. Components: age, history of congestive heart fail-
ure, history of MI, resting heart rate, systolic blood 
pressure, ST-segment depression, initial serum cre-
atinine, elevated cardiac enzymes, no in-hospital 
percutaneous coronary intervention.
b. Cut-off: we will define the score <140 AND negative 
troponin at 0 and 2 hours.
Hs-troponin-based strategies
Hs-troponin-based strategies are comprised of hs-tro-
ponin only, with cut-off values being troponin specific, as 
shown below for the five algorithms that will be used in 
the study. If a troponin value is below the cut-off values of 
each strategy, we regard a patient as being at low risk for 
an MI. In the High-STEACS pathway, a second troponin 
measurement is obtained 3 hours from presentation to 
the ED.25 Because there is often a delay of up to 1 hour 
for the first blood sample, the average time between the 
first and second troponin measurement is 2 hours, and 
therefore, we include the High-STEACS pathway without 
modification.
1. The 0 hour algorithm.36 37
a. Roche hs-troponin T: 0 hour <5 ng/L(*1).
b. Abbott hs-troponin I: 0 hour <2 ng/L(*2).
c. Siemens hs-troponin I: 0 hour <3 ng/L(*3).
d. Siemens sensitive-troponin I: 0 hour <0.5 ng/L(*4).
2. The 1 hour algorithm.23 37–39
a. Roche hs-troponin T: 0 hour <12 ng/L AND Δ0-1 
hour <3 ng/L(*5)
b. Abbott hs-troponin I: 0 hour <5 ng/L AND Δ0-1 
hour <2 ng/L(*6)
c. Siemens hs-troponin I: 0 hour <6 ng/L AND Δ0-1 
hour <3 ng/L(*7)
d. Siemens sensitive-troponin I: 0 hour <10 ng/L AND 
Δ0-1 hour <4 ng/L(*8)
3. The 2 hour algorithm.24 39 40
a. Roche hs-troponin T: 0 and 2 hour<14 ng/L AND 
Δ0-2 hour <4 ng/L.
b. Abbott hs-troponin I: 0 and 2 hour<6 ng/L AND 
Δ0-2 hour <2 ng/L
c. Siemens sensitive-troponin I: 0 and 2 hour <10 
ng/L.
4. The 0 and 1 hour algorithm.10 37
a. Roche hs-troponin T: *1 OR *5.
b. Abbott hs-troponin I: *2 OR *6.
c. Siemens hs-troponin I: *3 OR *7.
d. Siemens sensitive-troponin I: *4 OR *8.
5. The High-STEACS pathway (only for Abbott hs-tropo-
nin I at the moment).25
a. If hs-troponin I at 0 hour <5 ng/L AND symptom 
onset ≥2 hours, AMI is ruled out.
b. If 5≤ hs-troponin I at 0 hour ≤26.2 ng/L OR symp-
tom onset <2 hours, hs-troponin I at 2 hours is re-
quired. If Δ0-2 hour hs-troponin I <3 ng/L AND 
hs-troponin I at 3 hours ≤26.2 ng/L, AMI is ruled 
out.
reference standard
Final diagnosis adjudication
Two cardiologists of each facility will independently 
adjudicate the final diagnosis based on the results of the 
follow-up telephone interview and all available clinical 
information obtained 30 days or more after the admis-
sion to the ED: each item of the clinical history; physical 
examination; laboratory tests (both in-house troponin 
and hs-troponin T taken at 0 and 3 hours); ECG; ultra-
sonography; cardiac stress test; radiological test; and 
coronary angiography. Disagreements will be resolved 
through discussions between the two cardiologists. If 
they are unable to reach consensus, a third cardiologist 
by copyright.
 o
n
 N
ovem
ber 14, 2019 at University of Edinburgh. Protected
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026985 on 3 September 2019. Downloaded from 
6 Tada M, et al. BMJ Open 2019;9:e026985. doi:10.1136/bmjopen-2018-026985
Open access 
will be consulted. All cardiologists will be masked from 
the results of index tests and the research hs-troponin 
obtained at 1 and 2 hours.
The diagnosis of MI will be made in accordance with 
the forth universal definition of MI,41 and classified as 
type 1, type 2, type 4b and myocardial injury. Briefly, an 
MI will be diagnosed if there is a significant rise and/or 
fall of troponin, with at least one value above the 99th 
percentile, in a clinical setting consistent with acute 
myocardial ischemia. We will adjudicate final diagnosis 
with each of hs-troponin assays (Roche hs-troponin T, 
Abbott hs-troponin I and Siemens hs-troponin I). We will 
use the same hs-troponin to adjudicate the final diagnosis 
as that used for index tests to avoid unequal incorpora-
tion bias. We will define a significant rise and/or fall for 
3 hours as 6 ng/L for Roche hs-troponin T; the relative 
increase of >50% of the respective 99th percentile value 
if the initial troponin value is equal or less than the 99th 
percentile value, and the relative increase of >20% of 
the initial value if the initial troponin values is greater 
than the 99th percentile value for Abbott hs-troponin I 
and Siemens hs-troponin I.23 26 Type 1 MI is defined as 
myocardial necrosis with symptoms suggestive of MI or 
test results which prove myocardial ischemia. Type 2 MI 
is defined as myocardial necrosis, with a condition other 
than coronary artery disease, which contributes to an 
oxygen supply-demand imbalance (eg, coronary artery 
spasm; tachyarrhythmia; respiratory failure; or anaemia). 
Type 4b is an MI associated with stent thrombosis.
Clinical outcomes
The primary clinical outcome will be the composite of 
type 1 MI and cardiac death within 30 days of the ED 
admission. We will add type 2 and 4b MI to the primary 
clinical outcome as a sensitivity analysis, because it will 
be occasionally difficult to differentiate type 1 MI and 
other types of MI. If patients consult an ED or cardiac 
service in the study facility again, emergency physicians 
or cardiologists will ask patients if they have had an MI 
or if they have undergone any cardiac tests or revascular-
isation in other hospitals. Because not all patients can be 
expected to consult a study facility again, research staffs 
will conduct structured telephone follow-up interview 
with all patients enrolled into the study, 30 days after the 
ED admission. At 30 days, if patients have either consulted 
a study facility again or if sufficient clinical information 
is available, we will include only type 1 MI as the primary 
clinical outcome. While for patients who do not consult a 
study facility again and, therefore, only information from 
the telephone follow-up is for clinical outcomes, it will be 
difficult to differentiate type 1 MI from other types of MI. 
In these cases, we will include all MI types (1, 2 and 4b) as 
the primary clinical outcome. Similarly, the adjudication 
of a cause of death might be difficult in some patients. 
In this case, we will include an unknown cause of death 
into our primary outcome. Patients who do not consult 
a study facility again and could not be reached for the 
telephone follow-up interview will be excluded from the 
primary and secondary research objectives.
Sample size calculation
Assuming that the event rate of the primary clinical 
outcome is 5%–10%,6 11 with a sensitivity and specificity of 
the clinical impression-based strategies of 95% and 55%, 
respectively,42 1500 patients will need to be enrolled into 
the study if the lower limit of 95% CI of the NPV is to 
surpass 98%.
data analysis
Missing values
For missing values in clinical assessments, we will use 
the multiple imputation technique to minimise bias and 
preserve study power. We will also perform complete case 
analysis as a sensitivity analysis.
Primary research objective
We will describe the NPV, sensitivity and effectiveness of 
the three clinical impression-based strategies, using the 
95% CI for each troponin. We will also calculate the speci-
ficity, positive predictive value and area under the receiver 
operating characteristic curve (AUC) for each strategy. 
We will derive a generalised score statistic to compare 
NPV, and use the McNemar test to compare sensitivity 
and effectiveness. We will regard a strategy as being clin-
ically useful if the point estimate for NPV is ≥99%. If the 
point estimate for NPV is ≥99%, we will regard a strategy 
with shorter observational period as superior.
Secondary research objective 1
We will describe the NPV, sensitivity, effectiveness, AUC 
for the clinical impression-based strategies, prediction 
rules and hs-troponin-based strategies for each troponin. 
If the point estimate for NPV is ≥99%, we will regard a 
strategy with higher effectiveness and/or shorter observa-
tional period as superior.
Secondary research objective 2
Reliability will be evaluated for 300 consecutive patients. 
We will use Cohen’s weighted Kappa-statistic and the 
boot-strap method, with 1000 replications, to determine 
the 95% CI boundaries of reliability.
Sensitivity analysis
A sensitivity analysis will be performed including type 
2 and 4b MI to the primary clinical outcome. We will 
compare the NPV, sensitivity and effectiveness of the 
index tests between subgroups stratified by: time from 
symptom onset to hospital arrival; the clinical impres-
sion-based risk estimation; previous history of ischaemic 
heart disease or revascularisation; age; sex; and presence 
of chest pain considering its certainty. We will define the 
cut-off of the clinical impression-based risk estimation as 
neither moderate nor high. We also perform analyses by 
changing the cutoffs of other strategies. We will combine 
the hs-troponin-based strategies with clinical impres-
sion-based risk estimation and/or ECG, and evaluate 
by copyright.
 o
n
 N
ovem
ber 14, 2019 at University of Edinburgh. Protected
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026985 on 3 September 2019. Downloaded from 
7Tada M, et al. BMJ Open 2019;9:e026985. doi:10.1136/bmjopen-2018-026985
Open access
the NPV, sensitivity and effectiveness. We will use each of 
Roche Elecsys hs-troponin T; Siemens ADVIA Centaur 
hs-troponin I; and Siemens ADVIA Centaur sensitive-tro-
ponin I for the adjudication of MI. We will use sex-spe-
cific 99th percentiles of three types of hs-troponin for the 
index tests. We will perform complete case analysis for 
primary and secondary research objectives.
Ethics and dissemination
This study is approved by the Ethics Committees of the 
Kyoto University Graduate School and Faculty of Medi-
cine (R1380, 27 February 2018) and the five hospitals 
where we will recruit patients. We will disseminate the 
results of the study through peer-reviewed journals and 
conference presentations. For the study participants, we 
will disseminate the brief summary of the results of the 
study to all the EDs of study hospitals.
Patient and public involvement
Patients were not involved in the design of this study and 
asked for input in the creation of this article.
Summary
Along with the advance in troponin monitoring, the 
early management of MI suspected patients is markedly 
changing. Though many troponins are available now, 
diagnostic accuracy and cut-off values are specific for 
each type of troponin. Although many prediction-rules 
and hs-troponin-based strategies have been published, it 
is still unknown if these algorithms are superior to clin-
ical impression-based strategies. The study will be the first 
prospective study to compare clinical impression-based 
strategies, using four different types of troponin that are 
commonly used to estimate the risk of an MI with predic-
tion-rules and hs-troponin-based strategies. We will also 
evaluate the inter-rater reliability of the clinical impres-
sion-based risk estimation, and discuss the usefulness of 
these strategies, considering both the diagnostic accuracy 
and the inter-rater reliability.
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